To compare breast cancer prognosis in BRCA1 and BRCA2 mutation carriers with that in patients with sporadic disease.
INTRODUCTION
Germline mutations in BRCA1 or BRCA2 may account for up to 5% of breast cancers. It has been suggested that breast cancer prognosis may differ in women with germline mutations in these genes compared with those with sporadic breast cancer, 1 given the more frequent occurrence of adverse tumor characteristics in BRCA-associated cancers.
2-8 However, with treatment, prognosis may be enhanced in BRCA-associated breast cancers, because these cancers may be more sensitive to chemotherapy that causes DNA breaks (eg, alkylating agents, platinum), reflecting the role of BRCA protein products in repair of doublestranded DNA breaks.
More than 20 studies have investigated breast cancer prognosis in women with BRCA mutations, 1,9-32 with inconsistent results. Early studies suggested prognosis may be better in BRCAassociated breast cancer, 9-12 whereas more recent studies, using stronger designs, [25] [26] [27] [28] [29] [30] [31] [32] have suggested the opposite may be true. 30 As discussed recently by Bordeleau et al, 1 these discrepant results can be explained to a large extent by the underlying study methodologies used.
Enhanced understanding of prognostic implications of BRCA mutation status in early breast JOURNAL OF CLINICAL ONCOLOGY cancer will provide women with BRCA mutations with more accurate prognostic information, and it may also influence the decisions they make about breast cancer treatment, preventive surgery, and screening. We conducted a prospective population-based study of prognostic effects of BRCA1 and BRCA2 mutations at three sites (Ontario, Canada; Sydney and Melbourne, Australia; northern California, United States) of the Breast Cancer Family Registry (BCFR) to investigate these issues.
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PATIENTS AND METHODS
Study Population
Female patients with incident invasive breast cancer were ascertained through population-based cancer registries using eligibility and sampling criteria to enrich samples for BRCA-associated breast cancer. Identification of study patients is described in detail elsewhere. 34 Key information is provided here. Patients provided written informed consent to participate, as approved by the institutional review boards of the participating centers.
In Ontario, patients with breast cancer diagnosed between January 1, 1996, and December 31, 1998, were identified; all those younger than 55 years of age and a 35% random sample of those age 55 to 69 years were contacted. All patients who met prespecified criteria associated with increased genetic susceptibility were enrolled. Others were sampled at 25%. Of 2,390 patients invited, 1,227 provided epidemiologic and family history data and a blood sample. Participation did not differ by family history but was lower in nonwhite women.
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Patients with a history of invasive cancer and those who did not consent to medical-record access were excluded from this analysis, leaving 1,072 patients.
In northern California, patients with breast cancer diagnosed between January 1, 1995, and December 31, 2000, were identified and contacted. All patients who met prespecified criteria associated with increased genetic susceptibility were enrolled. Others were randomly sampled at 5% for nonHispanic whites and 16% for others. Of the 2,035 patients invited to participate, 1,121 provided epidemiologic and family history data and a blood sample. We excluded those with a history of invasive cancer and those who did not consent to medical-record access, leaving 1,041 patients.
In Australia, patients with breast cancer diagnosed between June 1, 1991, and June 30, 1998 (Melbourne), or between January 1, 1996, and June 30, 1998 (Sydney), were identified. All patients age 18 to 39 years were selected. In Melbourne, patients age 40 to 49 years were sampled at 41%, and those age 50 to 59 years at 25%; in Sydney, corresponding rates were 25% and 28%, respectively. Of 2,020 patients invited to participate, 1,107 without a history of invasive cancer who provided epidemiologic and family history data, a blood sample, and consent for access to medical records were included.
All patients provided information on family history and breast cancer risk using standard questionnaires; attempts were made to verify cancers in family members. After enrollment, patients were grouped using prespecified criteria: one, BRCA1 mutation carriers if a deleterious mutation in BRCA1 was identified; two, BRCA2 mutation carriers if a deleterious mutation in BRCA2 was identified; three, other familial breast cancer if there was a reported history of breast and/or ovarian cancer in a first-or second-degree relative at diagnosis in the absence of a known BRCA mutation; and four, sporadic breast cancer (all others). Survival was similar in groups three and four. 34 Group four (sporadic breast cancer), our protocol-specified comparison group, was included in all analyses; group three was not included in further analysis.
Clinical Data Collection
Clinical data were abstracted from medical records, supplemented with cancer registry data in California. Data included: menopausal status, method of breast cancer detection, date of diagnosis, TNM stage, treatment (surgical, radiation, chemotherapy, hormones), status of breasts and ovaries at diagnosis and follow-up, breast cancer recurrences, new primary cancers, and death. Date of birth, race, ethnicity, height, and weight were obtained from the epidemiologic questionnaire.
Pathology data, including tumor stage, nodal status, Elston's modification of the Bloom and Richardson grade, lymphovascular invasion, and estrogen receptor (ER)andprogesteronereceptor(PgR)statuswereobtainedfrompathologyreview or pathology reports, supplemented with cancer registry data in California.
DNA Testing
BRCA1 and BRCA2 mutation testing was performed using three DNA-based methods (two-dimensional gene scanning, denaturing highperformance liquid chromatography, and enzymatic mutation detection) and an RNA-based method (protein truncation).
36,37 Some mutation testing was conducted by Myriad Genetics (Salt Lake City, UT) using fullsequence analysis. Mutations classified as deleterious according to the Breast Information Core (http://research.nhgri.nih.gov/bic/) and Myriad Genetics Laboratories were included. In Ontario, BRCA1 and BRCA2 testing was performed in all high-risk patients and testing for Ashkenazi founder mutations in all Ashkenazi women. On the basis of mutation detection rates in low-risk women participating in the BCFR in Australia and California, the estimated false-negative rate for BCRA1 and BRCA2 mutations was approximately 2% in untested sporadic patients. 37 In California and Australia, all patients were tested for BRCA1 and BRCA2 mutations, with more extensive testing in probands with strong family history in Australia. 38 Samples for DNA testing were obtained at study enrollment (mean, 1.5 Ϯ 1.0 years [standard deviation] after diagnosis), but mutation testing was performed years later; results did not influence adjuvant treatment decisions.
Statistical Analysis
Patient characteristics were compared using Pearson's 2 test for categorical variables and t tests for continuous variables. Time to distant recurrence was calculated as the time from diagnosis to first distant recurrence; or from diagnosis to censoring at death or earliest nonbreast primary cancer diagnosis, if either occurred before distance recurrence; or from diagnosis to censoring at date of last follow-up, if still alive and distant-disease free at last follow-up. Time to death was calculated as the time from diagnosis to death, or to censoring if still alive at last follow-up.
The univariable effect of key tumor characteristics on risk of distant recurrence and death was examined within each patient group (BRCA1, BRCA2, sporadic disease). We conducted univariable and multivariable sitestratified Cox regression analyses comparing risk of distant recurrence and death between patients with sporadic disease, BRCA1 mutation carriers, and BRCA2 mutation carriers. Three patients without follow-up did not contribute to these analyses. Hazard ratios (HRs) and 95% CIs were estimated, adjusting for age (continuous), tumor and nodal stage, tumor grade, ER and PgR status, and year of diagnosis (continuous). We also examined outcomes in prespecified subsets defined by adjuvant chemotherapy and hormone therapy.
Differential effects between subgroups were tested using interaction terms. Oophorectomy in premenopausal women was not included in the primary models, because more than 25% of the data were missing, and most oophorectomies (72%) were performed more than 2 years after diagnosis. Oophorectomy within 2 years of diagnosis (considered adjuvant treatment) was examined on an exploratory basis. Analyses of risk of distant recurrence included only patients without metastases at diagnosis. Wald P values are reported. Because patients were enrolled at variable times post diagnosis (mean 1.5 Ϯ 1.0 years [standard deviation]), and 2% to 3% of potential patients died before enrollment, 33 we conducted analyses that left truncated time to death at the date of enrollment. Results were the same as those from our protocol-specified nontruncated analyses; results of the latter are presented here. We also conducted analyses that used distant relapse-free survival (including distant recurrences and all deaths as events) 39 ; results were the same as those from analyses of our protocol-specified end points, and only the latter are presented here.
RESULTS
Study Population Characteristics
The study population included 94 women with BRCA1 mutations, 72 with BRCA2 mutations, and 1,550 with sporadic breast cancer ( Table 1) . One woman with both a BRCA1 and BRCA2 mutation was included in both mutation groups. The 1,505 women with familial breast cancer not associated with BRCA1 or BRCA2 mutations were not included in our analyses. Median follow-up was 7.9 years. Mean age at diagnosis was 45.3 years. BRCA1 and BRCA2 mutation carriers were younger than those with sporadic disease (39.8 and 42.2 v 45.7 years; P Ͻ .001 and P ϭ .003, respectively). Compared with patients with sporadic disease, BRCA1 mutation carriers were less likely to have stage 1 tumors (51% v 63%; P Ͻ .001); axillary nodal involvement was more common in BRCA2 mutation carriers (56% v 45%; P ϭ .02). Both BRCA1 and BRCA2 mutation carriers were more likely to have high-grade tumors than those with sporadic disease (95% and 89% v 77%, respectively; P Ͻ .001 for both comparisons). BRCA1 mutation carriers were less likely to have ER-positive or equivocal tumors (25.5% v 68.7%; P Ͻ .001) or PgR-positive or equivocal tumors (37.2% v 66.8%; P Ͻ .001) than those with sporadic disease. They were also less likely to receive adjuvant hormonal therapy than those with sporadic disease (30% v 45%; P ϭ .010). Both BRCA1 and BRCA2 mutation carriers were more likely to receive adjuvant chemotherapy (including anthracyclines) than those with sporadic disease (85% and 79% v 60%, respectively; P Ͻ .005 for both comparisons). Postdiagnosis oophorectomy was more frequent in BRCA1 and BRCA2 mutation carriers than in those with sporadic disease (30.9% and 25.0% v 4.4%, respectively; P Ͻ .001 for both comparisons); median times to oophorectomy were 2.8 years in BRCA1 mutation carriers, 4.8 years in BRCA2 mutation carriers, and 3.4 years in those with sporadic disease.
Expected prognostic associations of key tumor characteristics were present in those with sporadic disease (Table 2) . Higher tumor stage, greater nodal involvement, higher tumor grade, and ER negativity were all associated with increased risk of recurrence or death. Axillary node involvement was associated with worse outcomes in BRCA1 (P ϭ .11 for distant recurrence; P ϭ .048 for death) and BRCA2 mutation carriers (P ϭ .083 for distant recurrence, P ϭ .081 for death). Prognostic associations of tumor stage and grade were attenuated in BRCA1 and BRCA2 mutation carriers and did not reach statistical significance.
Prognostic Associations of BRCA1 Mutations
Compared with those with sporadic cases, BRCA1 mutation carriers had similar risk of distant recurrence (HR, 1.19; 95% CI, 0.74 to 1.89; P ϭ .47) and death (HR, 1.43; 95% CI, 0.91 to 2.23; P ϭ .12; Table  3 ; Figs 1A, 1B) in univariable analyses. In multivariable analyses (ad- justed for age, tumor and nodal stage, grade, ER and PgR status, and year of diagnosis), no significant differences were identified (HR for distant recurrence, 0.83; 95% CI, 0.51 to 1.35; P ϭ .46 and HR for death, 0.99; 95% CI, 0.62 to 1.59; P ϭ .98). BRCA1 mutation carriers were more likely to receive adjuvant chemotherapy than those with sporadic disease (85.1% v 60.0%; P Ͻ .005); however, in neither the chemotherapy-treated nor -untreated groups did the risk of distant recurrence or death differ significantly from that in those with sporadic disease in multivariable analyses. BRCA1 mutation carriers were significantly less likely than those with sporadic disease to receive adjuvant tamoxifen (29.8% v 45.2%; P ϭ .01); among those with hormone receptor-positive tumors, tamoxifen was used in 51% and 54%, respectively (P ϭ .73). In multivariable analyses, risks of distant recurrence and death were similar in BRCA1 mutation carriers and those with sporadic disease with hormone receptore-negative or -positive breast cancer (regardless of whether they received adjuvant tamoxifen; all P Ն .32). Inclusion of postdiagnosis oophorectomy in premenopausal women as an adjuvant hormonal therapy (within 2 years or at any time) did not alter these associations.
Prognostic Associations of BRCA2 Mutations
In univariable analyses, when compared with those with sporadic disease, BRCA2 mutation carriers had a significantly higher risk of distant recurrence (HR, 1.63; 95% CI, 1.02 to 2.60; P ϭ .04) and death (HR, 1.81; 95% CI, 1.15 to 2.86; P ϭ .01; Table 4 ; Figs 1C, 1D) ; these differences did not persist in multivariable analyses (adjusted for age, tumor and nodal stage, grade, ER and PgR status, and year of diagnosis; HR for distant recurrence, 1.00; 95% CI, 0.62 to 1.61; P ϭ 1.00 and HR for death, 1.12; 95% CI, 0.70 to 1.79; P ϭ .64). BRCA2 mutation carriers were more likely to receive adjuvant chemotherapy than those with sporadic disease (79.2% v 60.0%; P ϭ .002). In the group that did not receive adjuvant chemotherapy, risk of death was significantly increased in BRCA2 mutation carriers compared with those with sporadic disease (HR, 3.62; 95% CI, 1.46 to 8.99) in multivariable analyses. In contrast, risk of death was similar in BRCA2 mutation carriers and those with sporadic disease when adjuvant chemotherapy was administered (HR, 0.94; 95% CI, 0.54 to 1.65). There were no significant differences between BRCA2 mutation carriers and those with sporadic disease in risk of distant recurrence, regardless of whether adjuvant chemotherapy was administered. The frequency of adjuvant hormone therapy use was similar in BRCA2 mutation carriers and patients with sporadic disease (54.2% v 45.2%; P ϭ .33; Table 1 ). When adjuvant hormone therapy was administered, risk of death was significantly increased in BRCA2 mutation carriers compared with those with sporadic disease (HR, 2.05; 95% CI, 1.07 to 3.91) in multivariable analyses. This was not seen when adjuvant hormones were not administered (HR, 0.69; 95% CI, 0.32 to 1.49). There were no significant differences between BRCA2 mutation carriers and those with sporadic disease in risk of distant recurrence, regardless of whether adjuvant hormone therapy was administered (all P Ն .58). Inclusion of postdiagnosis oophorectomy in premenopausal women (within 2 years of diagnosis or at any time) did not change these associations.
DISCUSSION
In this study, to our knowledge, we provide the first evidence that women with breast cancer and BRCA2 mutations have worse prognosis than women diagnosed with breast cancer at the same age who do not carry a BRCA2 mutation. A similar trend was reported by Rennert et al. 30 When we adjusted our analysis for the effects of tumor-and treatment-related variables, prognosis was similar in both groups of women, reflecting the fact that BRCA2 mutation carriers presented with cancers with more aggressive tumor characteristics than women without BRCA mutations. Our unadjusted result is meaningful to BRCA2 mutation carriers who have not developed breast cancer who are concerned not only about whether they will develop breast cancer but also about how aggressive it will be. The adjusted result is more relevant to carriers who have been diagnosed with breast cancer; it suggests prognosis is best predicted by the characteristics of the cancer that has developed rather than by carrier status. Outcomes were similar in BRCA1 mutation carriers and patients with sporadic disease.
Our findings differ from some earlier reports. 14,19,21,25 One major difference is that a high proportion (85%) of our BRCA1 mutation carriers received adjuvant chemotherapy. This frequent use of adjuvant chemotherapy may have reflected the younger age of BRCA1 mutation carriers (mutation status was unknown when treatment decisions were made) and contributed to their good prognosis. Our observations may be less relevant in women who do not receive adjuvant chemotherapy. It is possible that knowledge of carrier status at diagnosis might influence treatment decisions, leading to different outcomes. This should be investigated in future work.
Caution should be exercised in withholding adjuvant chemotherapy in the face of favorable tumor characteristics in BRCA1 and BRCA2 mutation carriers. Although we observed that some factors, such as axillary node involvement, were associated with poor outcomes regardless of BRCA mutation status, others, such as tumor stage and grade, were less strongly associated with outcomes in BRCA mutation carriers. Our observations regarding tumor stage are consistent with previous observations that prognosis may be poor in BRCA1 mutation carriers with small nodenegative tumors. 17 The differential effects we identified for adjuvant chemotherapy administration and outcome in BRCA2 mutation carriers versus those with sporadic disease should be interpreted cautiously. Although this examination was hypothesis driven, the number of events in carriers was low, and multiple tests were conducted; it is possible these results occurred by chance. They require replication in other datasets. Nonetheless, the differential chemotherapy effect in BRCA2 mutation carriers is in keeping with biologic evidence suggesting that chemotherapeutic agents causing DNA breaks may have enhanced activity in BRCA carriers.
Our findings regarding use of adjuvant tamoxifen therapy in BRCA2 mutation carriers were unexpected, and their interpretation requires an additional level of caution. We do not believe they should influence clinical practice. The worse survival we observed in BRCA2 mutation carriers who received tamoxifen was not the result of differential use of adjuvant chemotherapy in women who did and did not receive adjuvant tamoxifen (60% v 60% for those with sporadic disease; 82% v 78% for BRCA2 mutation carriers). Further research is needed to determine whether our findings can be replicated and to understand their biologic basis. One report suggests that impaired tamoxifen metabolism (resulting from reduced CYP2D6 activity) may result in worse survival in BRCA mutation carriers. 40 Other mechanisms, such as acquisition of tamoxifen resistance through altered expression of estrogen-responsive proteins, 41 may be relevant. Our study has several strengths. It was a prospective populationbased study of prognostic effects of BRCA1-and BRCA2-associated breast cancer. It was international and included many women who received anthracycline-based adjuvant therapy (none received taxanes). A focus on incident cancers reduced selection biases. Study limitations include the relatively small numbers of BRCA1 and BRCA2 mutation carriers and small number of events that occurred in these carriers, which may have limited the precision of estimates of main effects, reduced statistical power, and led to chance observations. We had information on type of chemotherapy administered but not on doses delivered. Although we explored prognostic effects of postdiagnosis oophorectomy in premenopausal women, power was limited (eg, only four premenopausal BRCA2 mutation carriers underwent this procedure), and we cannot exclude beneficial prognostic effects. Finally, we did not examine effects of breast surgery (lumpectomy v mastectomy) on locoregional events or other outcomes.
In summary, breast cancers in BRCA1 and BRCA2 mutation carriers differ at presentation from those in women with sporadic breast cancer. Outcomes in carriers of BRCA1 mutations, a large majority (85%) of whom received adjuvant chemotherapy, were similar to outcomes in patients with sporadic disease. Risk of distant recurrence and death was significantly higher in BRCA2 mutation carriers when compared with those with sporadic disease in univariable analyses, a difference that resulted from the presence of more adverse tumor characteristics at diagnosis in mutation carriers. Our observations suggest that BRCA mutation carriers diagnosed with breast cancer who receive standard adjuvant treatment may fare as well as those who do not carry mutations of the same age who present with similar cancers.
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